UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000008812
Receipt No. R000010359
Official scientific title of the study Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant cell arteritis or Takayasu arteritis) and polymyalgia rheumatica (PMR)
Date of disclosure of the study information 2012/10/01
Last modified on 2018/08/09 (Ver. 8)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant cell arteritis or Takayasu arteritis) and polymyalgia rheumatica (PMR)
Title of the study (Brief title) Treatment of LVV and PMR by tocilizumab mono-therapy
Region
Japan

Condition
Condition Rheumatoid arthritis
Classification by specialty
Clinical immunology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate the efficacy and safety of tocilizumab monotherapy for LVV and PMR
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase

Assessment
Primary outcomes mprovement of major clinical signs and symptoms at week 12(fever,abnormal findings of temporal artery, myalgia, serum CRP, ESR, abnormal radiological findings of the affected vessels)
Key secondary outcomes Improvement of major clinical signs at week 52, relapse rate and adverse events during 52 weeks

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 tocilizumab monotherapy
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
16 years-old <=
Age-upper limit
80 years-old >
Gender Male and Female
Key inclusion criteria Patients who fulfilled the 1990 ACR classification criteria for giant cell arteritis and Takayasu arteritis and the 2012 EULAR/ACR provisional classification criteria for PMR
1) Bloch DA, et al.: The ACR 1990 criteria for the classification of vasculitis. Patients and methods. Arthritis Rheum 1990; 33:1068-1073
2) Dasgupta B, et al.: 2012 Provisional classification criteria for polymyalgia rheumatica: a EULAR/ACR collaborative initiative. Arthritis Rheum 2012; 64: 943-954

Key exclusion criteria 1) patients who are prohibited to use tocilizumab by the JCR guideline for proper tocilizumab use
2) patients who are thought to be inappropriate for the treatment with tocilizumab by their attending doctor
Target sample size 40

Research contact person
Name of lead principal investigator Koichi Amano
Organization Saitama Medical Center,
Saitama Medical University
Division name Department of Rheumatology and Clinical Immunology
Address 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan
TEL 049-228-3859
Email amanokoi@saitama-med.ac.jp

Public contact
Name of contact person Ryota Sakai
Organization Saitama Medical Center, Saitama Medical Universitity
Division name Department of Rheumatology & Clinical Immunology
Address 1981 Kamoda Kawagoe, Saitama 350-8550
TEL 0492283574
Homepage URL
Email r_sakai@saitama-med.ac.jp

Sponsor
Institute Department of Rheumatology & Clinical Immunology
Saitama Medical Center, Saitama Medical Universitity
Institute
Department

Funding Source
Organization Department of Rheumatology & Clinical Immunology
Saitama Medical Center, Saitama Medical Universitity
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2012 Year 10 Month 01 Day

Progress
Recruitment status Completed
Date of protocol fixation
2012 Year 10 Month 01 Day
Anticipated trial start date
2012 Year 10 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Partially published
URL releasing results
Results
Other related information

Management information
Registered date
2012 Year 08 Month 30 Day
Last modified on
2018 Year 08 Month 09 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010359